Möchten Sie immer auf dem neuesten Stand bleiben?

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including...

Featured in The Wall Street Journal, Impact Analytics’ report warns GLP-1 adoption could put over $5B in retail sales at risk.

TORONTO, June 04, 2026 (GLOBE NEWSWIRE) -- GLP North, a Canadian supplier focused on ready-to-use research pen formats, has added Retaject availability to its Canadian research catalogue. The...

Arlington, VA, June 01, 2026 (GLOBE NEWSWIRE) -- New online community brings together people navigating GLP-1 medications, diabetes, obesity, metabolic health, and related conditions to learn,...

Kailera will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, at 10:30 am EDT.

Serotonin Centers opens new Lake Nona longevity center offering physician-led wellness, diagnostics, hormone optimization and recovery therapies.

Felix expands lower-cost GLP-1 access, offering Ozempic at generic-level pricing with free-start program and ongoing clinical support

Exton, PA, May 27, 2026 (GLOBE NEWSWIRE) -- As the obesity treatment landscape rapidly evolves, newly launched oral GLP-1 based treatments are introducing alternate treatment options for patients...

Phase 2 and Phase 3 trials are reshaping expectations across obesity, oncology, gene editing, autoimmune disease, and neurological disorders.